Biohaven (BHVN) reported a reduced net loss of $137.31 million for Q2 2026, with a loss per share of $0.91, significantly improved from a loss of $1.94 per share a year earlier. Over the first half of 2026, the company recorded a net loss of $267.84 million, narrowing its loss per share from $4.11 in the prior period. Despite a recent 46.56% jump in share price over 90 days, the overall one-year shareholder return is down 11.27%. Biohaven’s stock trades at a remarkably high price-to-book (P/B) ratio of 171.2x, far exceeding the biotech industry average of 2.5x, indicating the market is pricing in substantial future potential despite current losses and minimal revenue. Investors face a dilemma: whether the stock is overvalued based on current assets or if the pipeline and future earnings are undervalued.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/is-biohaven-bhvn-undervalued-following-its-latest-earnings-l
